Novocure Ltd (NVCR)

[jondoeuk]

Your post is a distortion—it is missing crucial context and is misleading.

No, it is not.

The DCVax-L cell-based platform technology was analyzed by an independent peer review that was published in JAMA Oncology.

The randomised and placebo controlled trial they ran was a failure:

mPFS: 7.6 months for placebo; 6.2 months for DCVax-L. Hazard ratio 1.1

mOS: 23.1 months for placebo; 22.4 months for DCVax-L. Hazard ratio so bad they wouldn't tell us.

But as long as you completely ignore that, along with many other things, and allow them to use a cherry-picked control instead, then there is a ''benefit"!

Comments about the publication are not peer reviewed and are not part of the medical literature.

They were from experts, including Prof. Stupp, who is an internationally renowned medical oncologist and neuro-oncologist, and a leading authority on primary and metastatic brain cancers. Prof. Stupp has been the lead investigator for numerous clinical trials from first-in-human to pivotal registrational trials, including two that lead to changes in the standard of care for patients with GBM. You are also forgetting the papers l linked to as well.